Symjepi (epinephrine) / DMK Pharma, US WorldMeds - LARVOL DELTA

An epinephrine nasal spray (neffy) for anaphylaxis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions (AAP-NCE 2024) - "effy (epinephrine nasal spray) was more stable than injection products and remained within shelf-life specifications for potency even after 3-months under extreme temperature conditions (50°C). EpiPen and Symjepi showed rapid and extensive degradation and were subpotent at these extreme temperature conditions after a short period of time. The expiration period for injection products is 18-months, while neffy, a needle-free epinephrine alternative, is anticipated to be launched with an initial expiration period of 24-months."

Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions (AAAAI 2024) - "neffy (epinephrine nasal spray) was more stable than injection products and remained within shelf-life specifications for potency even after 3-months under extreme temperature conditions (50°C). EpiPen and Symjepi showed rapid and extensive degradation and were subpotent at these extreme temperature conditions after a short period of time. The expiration period for injection products is 18-months, while neffy, a needle-free epinephrine alternative, is anticipated to be launched with an initial expiration period of 24-months."

Late-breaking abstract • Allergy

A Novel Method for Administering Epinephrine During Neonatal Resuscitation. (PubMed, Am J Perinatol) - "During simulated neonatal resuscitation, epinephrine preparation and administration are faster using novel prefilled epinephrine syringes, which may hasten return of spontaneous circulation and be lifesaving for bradycardic neonates in clinical practice."

Journal • Critical care

Use of eye-tracking to evaluate human factors in accessing neonatal resuscitation equipment and medications for advanced resuscitation: A simulation study. (PubMed, Front Pediatr) - "Participants were fitted with eye-tracking glasses then randomized to prepare two epinephrine doses using two methods, starting with an adult epinephrine prefilled syringe or a multiple access vial. Task-based kits were welcomed, but more orientation is needed. Eye-tracked simulations provided human factors assessment of emergency neonatal code carts and epinephrine preparation."

Journal • Metastases

Symjepi Epinephrine Injection Device Deconstruction and Residual Medication Retrieval in an Austere Environment. (PubMed, Wilderness Environ Med) - "Previous articles have demonstrated the deconstruction of spring-loaded epinephrine autoinjectors to extract additional medication doses. This article provides instruction and videography, outlining the process of deconstructing and obtaining additional doses of epinephrine from the Symjepi prefilled syringe."

Journal • Allergy • Immunology

"$AMPH Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes https://t.co/97bCdWNB2j #fdaapproval" (@stock_titan)

FDA event

"$ADMP Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect https://t.co/ZVDGwzWJ28" (@stock_titan)

Neffy Human Factor Findings (AAAAI 2022) - "In EPI 12, no dosing errors were reported with ARS-1. Dosing errors following EpiPen ranged from 8.3 to 33.3% of subjects in each period; dosing errors following Symjepi ranged from 11.1 – 22.2% of subjects in each period. The intended users demonstrated that they were able to safely and successfully use the Aptar Unit Dose System during an emergency scenario. This included dosing themselves or a simulated patient."

Allergy

Comparison of Pharmacokinetic Parameters and Intra-Blood Vessel Injection Rates Between Manual IM injection and Epinephrine Auto-Injectors (AAAAI 2022) - "While manual IM injection and EAIs are considered clinically comparable, both PK findings and intra-vessel injection rates suggest there are significant differences among these products."

PK/PD data

Anaphylaxis: Access to Epinephrine in Outpatient Setting. (PubMed, Immunol Allergy Clin North Am) - "Epinephrine prefilled syringes and epinephrine kits are lower-cost alternatives to EAIs. Advantages, disadvantages, and costs of available products are discussed and the socioeconomic factors impacting access to EAIs described. EAIs designed for infants also are discussed."

Clinical • Journal • Review • Allergy

"$ADMP SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products https://t.co/XVImf2C30T" (@stock_titan)

Utility of an educational video on epinephrine prefilled syringe usage for anaphylaxis: a randomized control trial. (PubMed, Asia Pac Allergy) - "This technique might be applied for patients in clinical practice. However, the further researches in general population are needed to confirm the efficacy of this method."

Clinical • Journal • Video • Allergy

Adamis Pharmaceuticals Provides Update on Symjepi Products (GlobeNewswire) - "Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC ('USWM' or 'US WorldMeds') began promoting Adamis’ Symjepi^® (epinephrine) injection 0.3 mg and Symjepi^® (epinephrine) injection 0.15 mg products through its field sales force....US WorldMeds is working closely with Sandoz to minimize market disruption while we increase our commercial and distribution efforts. We expect to complete the full transition from Sandoz during the third quarter of 2020."

Commercial • Allergy • Immunology

Adamis Pharmaceuticals provides update on Symjepi products and announces distribution and commercialization agreement for Symjepi and Zimhi products (GlobeNewswire) - "Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its Symjepi (epinephrine) injection 0.3 mg, Symjepi (epinephrine) injection 0.15 mg products currently marketed and available in the United States. Adamis has simultaneously entered into an exclusive distribution and commercialization agreement with US WorldMeds, LLC for the United States commercial rights for the Symjepi products."

Licensing / partnership • Allergy • Immunology